This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 3.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0 [5], updated to version 2.0 [6].
Arenaviruses are a type of small virus commonly found in rodents. When a person becomes infected with an arenavirus, symptoms usually begin within 10 days.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 28 January - 3 February 2024 and includes updates on SARS-CoV-2 variant classification, swine influenza, human cases of co-infection with seasonal influenza and avian influenza, influenza, western equine encephalitis, and an overview of respiratory virus epidemiology in the EU/EEA.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 21-27 January 2024 and includes updates on SARS-CoV-2, influenza, cholera, chikungunya, dengue and zika.
This report presents an interim description of COVID-19 vaccine coverage in the European Union/European Economic Area (EU/EEA) between 1 September 2023 and January 2024.
More frequent heatwaves and flooding, longer and hotter summers - all of these factors created more favourable conditions for mosquitos to thrive. Watch our animation, learn more and stay safe!
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 14-20 January 2024 and includes updates on avian influenza, SARS-CoV-2 variant classification, an overview of respiratory viruses in the EU/EEA, mpox, measles, and Infant formula for medical purposes recalled due to possible contamination with Cronobacter sakazakii.
This generic protocol for ECDC studies describes the design and methods for a prospective multi-country cohort study of hospital-based healthcare workers (HCWs) to evaluate the effectiveness of COVID-19 vaccine in preventing laboratory-confirmed SARS-CoV-2 infection.